Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of the Use of Beta-Blockers on Chronic Obstructive Pulmonary Disease Associated with Cardiovascular Comorbities: Systematic Review and Meta-analysis

  • Received : 2024.01.27
  • Accepted : 2024.03.29
  • Published : 2024.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Cardiovascular comorbidity is common in individuals with chronic obstructive pulmonary disease (COPD). This factor interferes with pharmacological treatment. The use of β-blockers has been proposed for their known cardioprotective effects. However, due to their adverse reactions, and the risk of causing bronchospasm, there is reluctance to use them. To summarize existing evidence on the effects of β-blocker use in COPD associated with cardiovascular comorbidities in relation to disease severity, exacerbation, and mortality outcomes. EMBASE, Medline, Lilacs, Cochrane Library, and Science Direct databases were used. Observational studies that evaluated the effects of β-blockers on individuals with COPD and cardiovascular comorbidities, and related disease severity, exacerbations, or mortality outcomes were included. Studies that did not present important information about the sample and pharmacological treatment were excluded. Twenty studies were included. Relevance to patient care and clinical practice: The use of β-blockers in individuals with COPD and cardiovascular disease caused positive effects on mortality and exacerbations outcomes, compared with the results of individuals who did not use them. The severity of the disease caused a slight change in forced expiratory volume in 1 second. The odds ratio for mortality was 0.50 (95% confidence interval [CI], 0.39 to 0.63; p<0.00001), and for exacerbations, 0.76 (95% CI, 0.62 to 0.92; p=0.005), being favorable to the group that used β-blockers. Further studies are needed to study the effect of using a specific β-blocker in COPD associated with a specific cardiovascular comorbidity.

Keywords

Acknowledgement

We thank the Stricto Sensu Graduate Program in Pharmaceutical Sciences (PPGFARMA) for their support and encouragement.

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2020 report [Internet]. Fontana: GOLD; 2020 [cited 2024 Apr 10]. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. 
  2. Oca MM, Varela MVI, Acuna A, Schiavi E, Rey MA, Jardim J, et al. Brazilian guidelines for the management of COPD (adaptation for Brazil of the Latin American Consensus of COPD) [Internet]. Asa Sul: Brazilian Society of Pulmonology and Tisiology; 2016 [cited 2024 Apr 10]. Available from: https://sbpt.org.br/consensos-diretrizes-nacionais. 
  3. Bottega TS. Comorbidities and mortality in chronic obstructive pulmonary disease (master's thesis). Porto Alegre: Federal University of Rio Grande do Sul; 2014. 
  4. Azambuja R, Bettencourt M, da Costa CH, Rufino R. Panorama da doenca pulmonar obstrutiva cronica [An overview of chronic obstructive pulmonary disease]. Rev HUPE 2013;12:13-8. 
  5. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65. 
  6. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013;162:237-51. 
  7. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?: the potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9. 
  8. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity: a common inflammatory phenotype? Respir Res 2006;7:70. 
  9. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009;11:1182-8. 
  10. Short PM, Anderson WJ, Elder DH, Struthers AD, Lipworth BJ. Impact of left ventricular hypertrophy on survival in chronic obstructive pulmonary disease. Lung 2015;193:487-95. 
  11. Funk GC, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC. Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure. Chest 2008;133:1354-9. 
  12. Boussuges A, Pinet C, Molenat F, Burnet H, Ambrosi P, Badier M, et al. Left atrial and ventricular filling in chronic obstructive pulmonary disease. an echocardiographic and Doppler study. Am J Respir Crit Care Med 2000;162(2 Pt 1):670-5. 
  13. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu CY, Rabinowitz D, et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. Chest 2013;144:1143-51. 
  14. Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016;48:880-8. 
  15. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41. 
  16. Fuchs SC, Paim BS. Revisao sistematica de estudos observacionais com metanalise [Meta-analysis and systematic review of observational studies]. Rev HCPA 2010;30:294-31. 
  17. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 
  18. Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004;117:925-31. 
  19. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-5. 
  20. van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008;178:695-700. 
  21. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-84. 
  22. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013;347:f6650. 
  23. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013;111:582-7. 
  24. Angeloni E, Melina G, Roscitano A, Refice S, Capuano F, Lechiancole A, et al. β-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg 2013;95:525-31. 
  25. Puente-Maestu L, Calle M, Ortega-Gonzalez A, Fuster A, Gonzalez C, Marquez-Martin E, et al. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med 2014;108:737-44. 
  26. Lee DS, Markwardt S, McAvay GJ, Gross CP, Goeres LM, Han L, et al. Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease. Med Care 2014;52 Suppl 3:S45-51. 
  27. Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015;10:515-23. 
  28. Dong YH, Chang CH, Wu LC, Lai MS. Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study. Eur J Clin Pharmacol 2016;72:1265-73. 
  29. Huang YL, Lai CC, Wang YH, Wang CY, Wang JY, Wang HC, et al. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis 2017;12:2987-96. 
  30. Oda N, Miyahara N, Ichikawa H, Tanimoto Y, Kajimoto K, Sakugawa M, et al. Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017;12:1119-24. 
  31. Key A, Parry M, West MA, Asher R, Jack S, Duffy N, et al. Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD. BMJ Open Respir Res 2017;4:e000164. 
  32. Liao KM, Lin TY, Huang YB, Kuo CC, Chen CY. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis 2017;12:2573-81. 
  33. Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis 2017;12:3041-6. 
  34. Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Gronke L, et al. β-Blockers in COPD: a cohort study from the TONADO research program. Chest 2018;153:1315-25. 
  35. Rezaei SS, Rinner C, Ratajczak P, Grossmann W, Gall W, Wolzt M. Use of beta-blocker is associated with lower mortality in patients with coronary artery disease with or without COPD. Clin Respir J 2018;12:2627-34. 
  36. Zvizdic F, Begic E, Mujakovic A, Hodzic E, Prnjavorac B, Bedak O, et al. Beta-blocker use in moderate and severe chronic obstructive pulmonary disease. Med Arch 2019;73:72-5. 
  37. Thomas CD, Dupree LH, DeLosSantos M, Ferreira JA. Evaluation of the protective effects of β-blockers in the management of acute exacerbations of chronic obstructive pulmonary disease. J Clin Pharm Ther 2019;44:109-14. 
  38. Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther 2008;21:115-24. 
  39. Ling Y, Saleem W, Shee CD. Concomitant use of beta-blockers and beta2-agonists. Eur Respir J 2008;31:905-6. 
  40. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7. 
  41. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J 2010;40:193-200. 
  42. Su VY, Chang YS, Hu YW, Hung MH, Ou SM, Lee FY, et al. Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine (Baltimore) 2016;95:e2427. 
  43. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005;127:818-24. 
  44. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003;123:222-43. 
  45. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;2005:CD003566. 
  46. Sessa M, Mascolo A, Mortensen RN, Andersen MP, Rosano GM, Capuano A, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail 2018;20:548-56. 
  47. Fallis BA, Dhalla IA, Klemensberg J, Bell CM. Primary medication non-adherence after discharge from a general internal medicine service. PLoS One 2013;8:e61735. 
  48. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002;137:715-25. 
  49. Malerba M, Montuschi P, Radaeli A, Pirisi M. Role of beta-blockers in patients with COPD: current perspective. Drug Discov Today 2015;20:129-35. 
  50. Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med 2013;1:564-73. 
  51. Dellaca RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009;33:1329-37. 
  52. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. 
  53. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2549.